DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/28wbzl/high)
has announced the addition of the “High
Triglyceridemia – Pipeline Review, H2 2015” report to their
This report provides comprehensive information on the therapeutic
development for High Triglyceridemia, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for High
Triglyceridemia and special features on late-stage and discontinued
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Acasti Pharma Inc.
- Allergan Plc
- Alnylam Pharmaceuticals, Inc.
- Arisaph Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- BASF SE
- Cardax Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals, Inc.
- CymaBay Therapeutics, Inc.
- Daiichi Sankyo Company, Limited
- Essentialis, Inc.
- Isis Pharmaceuticals, Inc.
- Jeil Pharmaceutical Co., Ltd.
- Michigan Life Therapeutics, LLC
- Novartis AG
- Pharmena SA
- Tekmira Pharmaceuticals Corp.
- Thetis Pharmaceuticals LLC
For more information visit http://www.researchandmarkets.com/research/28wbzl/high
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716